- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00886132
A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
July 22, 2015 updated by: University Health Network, Toronto
A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
This is a phase II study to evaluate the effectiveness of study drug sunitinib malate in patients with recurrent and/or metastatic adenoid cystic carcinomas of the salivary gland.
There currently is not standard of care for this type of cancer and it has hoped that sunitinib will have antitumor effects on patients with this type of cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label phase II study of sunitinib malate in patients with recurrent and/or metastatic adenoid cystic carcinomas (ACC) of major or minor salivary gland origin.
Sunitinib is a novel, multi-targeted small molecule inhibitor of the receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptors (VEGFs), platelet derived growth factor receptors (PDGFRs) and stem cell factor receptor (KIT), that are involved in tumour proliferation and angiogenesis.
VEGF expression has been associated clinically with disease prognosis in many different types of cancers and a number of studies have suggested that VEGF may play an important role in the pathogenicity of ACC.
Sunitinib is expected to inhibit PDGF- and VEGF-driven angiogenesis and, as a consequence, limit solid tumour growth.This study will determine the anti-tumour activity of sunitinib in ACC of the salivary glands using objective response rates (partial and complete responses) as its primary objective.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have histologic or cytologic adenoid cystic carcinomas of major or minor salivary gland origin.
Patients must have recurrent and/or metastatic disease that is progressive and not amenable to surgery or curative radiotherapy occurring within 6 months of study entry:
- at least a 20% increase in radiologically or clinically measurable disease;
- appearance of any new lesions or
- deterioration in clinical status
- Patients must have measurable disease, at least one lesion that can be accurately measured in at least one dimension as >20 mm with conventional techniques or as >10 mm with spiral CT scan.
- Patients with prior therapy with at least a 4 weeks' interval between any chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy or surgery and study enrollment. Exceptions may be made for low dose, non-myelosuppressive radiotherapy.
- Patients must be 18 years of age or older.
- Life expectancy of greater than 12 weeks.
Patients must have normal organ and marrow function as defined below:
- leukocytes >3,000/μL
- absolute neutrophil count >1,500/μL
- platelets >100,000/μL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal
- amylase/lipase within normal institutional limits
- creatinine within normal institutional limits
- creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- Cardiac ejection fraction within the institutional range of normal as measured by ECHO or MUGA scan.
- Patients must have QTc < 500 msec on baseline ECG.
Patients with New York Heart Association (NYHA) Class II cardiac function:
- with a history of Class II heart failure who are asymptomatic on treatment
- with prior anthracycline exposure
- who have received central thoracic radiation that included the heart in the radiotherapy port.
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. At least 4 weeks must have elapsed since any major surgery.
- Patients receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib.
- Patients with QTc prolongation or other significant ECG abnormalities.
- Patients with poorly controlled hypertension.
- Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis. Note: Low molecular weight heparin is permitted provided the patient's PT INR is <1.5.
- Patients with any condition that impairs their ability to swallow and retain sunitinib tablets.
Patients with any of the following conditions:
- Serious or non-healing wound, ulcer, or bone fracture.
- History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days of treatment.
- Any history of cerebrovascular accident or transient ischemic attack within 12 months prior to study entry.
- History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry.
- History of pulmonary embolism within the past 12 months.
- Class III or IV heart failure as defined by the NYHA.
- Patients taking medications that are potent inducers or inhibitors of the CYP3A4 liver enzyme (unless deemed acceptable by the Principal Investigator).
- Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication.
- Patients with known brain metastases.
- Patients with uncontrolled intercurrent illness including, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women. Breastfeeding should be discontinued if the mother is treated with sunitinib.
- HIV-positive patients on combination antiretroviral therapy
- Patients taking any of the medications that may cause QTc prolongation unless the required washout period has been met.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sunitinib
Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
|
37.5 mg taken orally, daily every 28-day cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the antitumor activity of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma of the salivary glands using objective response rates (partial and complete responses).
Time Frame: Changes in tumor measurements must be confirmed by repeat assessments that should be performed not less than 4 weeks after the criteria for response are first met.
|
Changes in tumor measurements must be confirmed by repeat assessments that should be performed not less than 4 weeks after the criteria for response are first met.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the duration of objective response, rate and duration of stable disease, progression-free, median and overall survival rates of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma of the salivary glands.
Time Frame: From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively.
|
From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sebastien Hotte, MD, Juravinski Cancer Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
April 20, 2009
First Submitted That Met QC Criteria
April 21, 2009
First Posted (Estimate)
April 22, 2009
Study Record Updates
Last Update Posted (Estimate)
July 23, 2015
Last Update Submitted That Met QC Criteria
July 22, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Stomatognathic Diseases
- Mouth Diseases
- Salivary Gland Diseases
- Mouth Neoplasms
- Carcinoma
- Carcinoma, Adenoid Cystic
- Salivary Gland Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- ACC-Siu 2006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenoid Cystic Carcinoma
-
Glenn J. HannaAdenoid Cystic Carcinoma Research Foundation; Cellestia Biotech AGRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic CarcinomaUnited States
-
Dana-Farber Cancer InstituteAdenoid Cystic Carcinoma Research Foundation; Gateway for Cancer ResearchRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic CarcinomaUnited States
-
Dana-Farber Cancer InstituteAdenoid Cystic Carcinoma Research FoundationNot yet recruitingAdenoid Cystic Carcinoma | Adenoid Cystic Carcinoma of the Salivary GlandUnited States
-
Peking Union Medical College HospitalRecruitingMetastatic Adenoid Cystic Carcinoma | 68Ga-FAPI PET/CTChina
-
Remix TherapeuticsRecruitingAdenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic CarcinomaUnited States
-
Fudan UniversityCompletedCisplatin | Adenoid Cystic CarcinomasChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMetastatic Adenoid Cystic Carcinoma | Progressive Disease | Recurrent Adenoid Cystic CarcinomaUnited States
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingAdenoid Cystic Carcinoma of the Head and NeckChina
-
Ayala Pharmaceuticals, Inc,Memorial Sloan Kettering Cancer Center; Hadassah Medical Organization; Adenoid... and other collaboratorsCompleted
Clinical Trials on Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenCompletedPlatinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian TubeGermany
-
Mothaffar RimawiTerminated
-
Cogent Biosciences, Inc.RecruitingMetastatic Cancer | Advanced Gastrointestinal Stromal TumorsUnited States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
PfizerCompletedBreast NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Asan Medical CenterCompletedMetastatic Renal Cell CarcinomaKorea, Republic of